183 related articles for article (PubMed ID: 37701690)
21. Multidisciplinary treatment for locally advanced gastric cancer: A systematic review and network meta-analysis.
Yu Z; Tu H; Qiu S; Dong X; Zhang Y; Ma C; Li P
J Minim Access Surg; 2023; 19(3):335-347. PubMed ID: 37282430
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery.
Terlizzi M; Buscail E; Boussari O; Adgié S; Leduc N; Terrebonne E; Smith D; Blanc JF; Lapuyade B; Laurent C; Chiche L; Belleannée G; Le Malicot K; Trouette R; Pouypoudat C; Vendrely V
Acta Oncol; 2021 Sep; 60(9):1114-1121. PubMed ID: 34197269
[TBL] [Abstract][Full Text] [Related]
23. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study.
Wang X; Huang J; Huang H; Liu Y; Ji C; Liu J
Invest New Drugs; 2023 Aug; 41(4):579-586. PubMed ID: 37368088
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis.
Lee YS; Lee JC; Yang SY; Kim J; Hwang JH
Sci Rep; 2019 Oct; 9(1):15662. PubMed ID: 31666626
[TBL] [Abstract][Full Text] [Related]
26. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
27. A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study.
Zhou M; Yang W; Xuan Y; Zou W; Wang Y; Zhang Z; Zhang J; Mo M; Zhou C; Liu Y; Zhang W; Zhang Z; He Y; Weng W; Tan C; Wang L; Huang D; Sheng W; Li H; Zhu H; Wang Y; Shen L; Zhang H; Wan J; Li G; Huang H; Wang Y; Zhang Z; Liu X; Xia F
BMC Cancer; 2022 Jun; 22(1):710. PubMed ID: 35764956
[TBL] [Abstract][Full Text] [Related]
28. A CT-based deep learning radiomics nomogram for predicting the response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A multicenter cohort study.
Cui Y; Zhang J; Li Z; Wei K; Lei Y; Ren J; Wu L; Shi Z; Meng X; Yang X; Gao X
EClinicalMedicine; 2022 Apr; 46():101348. PubMed ID: 35340629
[TBL] [Abstract][Full Text] [Related]
29. Posttherapy topographical nodal status, ypN-site, predicts survival of patients who received neoadjuvant chemotherapy followed by curative surgical resection for non-type 4 locally advanced gastric cancer: supplementary analysis of JCOG1004-A.
Fujitani K; Nakamura K; Mizusawa J; Kuwata T; Shimoda T; Katayama H; Kushima R; Taniguchi H; Yoshikawa T; Boku N; Terashima M; Fukuda H; Sano T; Sasako M;
Gastric Cancer; 2021 Jan; 24(1):197-204. PubMed ID: 32572792
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma.
Wang Z; He T; Yu D; Qin X; Geng A; Yang H
Exp Ther Med; 2022 Oct; 24(4):625. PubMed ID: 36160880
[TBL] [Abstract][Full Text] [Related]
31. Analysis of Patient Outcomes following Curative R0 Multiorgan Resections for Locally Advanced Gastric Cancer: A Systematic Review and Meta-Analysis.
Dejeu V; Dejeu P; Muresan A; Bradea P; Dejeu D
J Clin Med; 2024 May; 13(10):. PubMed ID: 38792552
[No Abstract] [Full Text] [Related]
32. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
Wijetunga AR; Chua TC; Nahm CB; Pavlakis N; Clarke S; Chan DL; Diakos C; Maloney S; Ashrafi-Zadeh A; Kneebone A; Hruby G; Jamieson NB; Gill A; Mittal A; Samra JS
Eur J Surg Oncol; 2021 Oct; 47(10):2543-2550. PubMed ID: 33952409
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.
Yang Z; Jiang X
BMC Gastroenterol; 2023 Apr; 23(1):122. PubMed ID: 37046191
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort.
Jiang Q; Liu W; Zeng X; Zhang C; Du Y; Zeng L; Yin Y; Fan J; Yang M; Tao K; Zhang P
Front Immunol; 2023; 14():1122121. PubMed ID: 37215127
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant chemotherapy in locally advanced gastric cancer: what to avoid. Preliminary analysis of a consecutive series of patients.
Rausei S; Lianos GD; Proserpio I; Ruspi L; Galli F; Frattini F; Mangano A; Rovera F; Boni L; Roukos DH; Pinotti G; Dionigi G
Tumori; 2015; 101(5):511-6. PubMed ID: 25908036
[TBL] [Abstract][Full Text] [Related]
37. Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial.
Pan L; Tian Y; Wang K; Tang J; Liu J; Zhang J; Wang M; Liu J; Xu H; Chen X
J Gastrointest Oncol; 2022 Dec; 13(6):3300-3313. PubMed ID: 36636043
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the predictive value of pathological response at primary tumor and lymph node status after neoadjuvant chemotherapy in locally advanced gastric cancer.
Su P; Zhang Y; Yu T; Jiang L; Kang W; Liu Y; Yu J
Clin Transl Oncol; 2023 Aug; 25(8):2462-2471. PubMed ID: 37093455
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant therapy for pancreatic cancer.
Gugenheim J; Crovetto A; Petrucciani N
Updates Surg; 2022 Feb; 74(1):35-42. PubMed ID: 34628591
[TBL] [Abstract][Full Text] [Related]
40. Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis.
Ratnayake B; Savastyuk AY; Nayar M; Wilson CH; Windsor JA; Roberts K; French JJ; Pandanaboyana S
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32640720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
